Study of Galectin-3 Levels and Their Link to Outcomes in Patients With Kidney, Bladder, Lung, and Liver Cancers Treated With PD-1PDL-1 Inhibitors

What this Trial Is About

Researchers are investigating the role of Galectin-3 Gal-3, a protein involved in cell processes and immune regulation, in patients with renal cell carcinoma, transitional cell carcinoma, non small cell lung cancer, and hepatocellular carcinoma treated with PD-1PDL-1 inhibitors. The study aims to understand how Gal-3 levels relate to treatment response, survival, and side effects, as Gal-3 may affect tumor progression and reduce the effectiveness of immunotherapy. This observational study involves measuring Gal-3 blood levels using an FDA-approved automated system called the Architect platform, ensuring accurate and consistent results. Blood samples are collected before each PD-1PDL-1 inhibitor treatment and stored for analysis. Clinical and laboratory data, including liver function and adverse events, are also collected throughout the study period. Participants will be monitored over three years with regular blood draws and clinical evaluations before each immunotherapy cycle. Researchers will analyze the correlation between Gal-3 levels and patient outcomes such as treatment response and side effects. The study seeks to improve understanding of how Gal-3 influences immunotherapy results to optimize future treatments for these cancers.

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors